Stent Thrombosis

David R. Holmes; Dean J. Kereiakes; Scot Garg; Patrick W. Serruys; Gregory J. Dehmer; Stephen G. Ellis; David O. Williams; Takeshi Kimura; David J. Moliterno

doi:10.1016/j.jacc.2010.07.016

Stent Thrombosis

David R. Holmes, Dean J. Kereiakes, Scot Garg, Patrick W. Serruys, Gregory J. Dehmer, Stephen G. Ellis, David O. Williams, Takeshi Kimura, David J. Moliterno

Research output: Contribution to journal › Review article › peer-review

376 Scopus citations

Abstract

Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.

Original language	English
Pages (from-to)	1357-1365
Number of pages	9
Journal	Journal of the American College of Cardiology
Volume	56
Issue number	17
DOIs	https://doi.org/10.1016/j.jacc.2010.07.016
State	Published - Oct 19 2010

Bibliographical note

Funding Information:
Dr. Kereiakes has received a grant and/or research support from Abbott Vascular , Cordis/Johnson & Johnson , Boston Scientific , and Medtronic ; and consulting fees from Abbott Vascular, Boston Scientific, Cordis/Johnson & Johnson, Devax, and REVA Medical Inc. Dr. Ellis is a consultant for Abbott Vascular, Boston Scientific, and Cordis. Dr. Williams is a consultant for Cordis. Dr. Kimura is an advisory board member for Codis Cardiology and Abbott Vascular. Dr. Moliterno is a consultant for Boston Scientific, Merck/Schering-Plough, Daiichi-Sankyo, and Sanofi-Aventis. All other authors report that they have no relationships to disclose.

Keywords

acute myocardial infarction
bare-metal stent
drugeluting stent
dual antiplatelet therapy
percutaneous coronary intervention
stent thrombosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.jacc.2010.07.016

Cite this

@article{e20e87f94e2f4fc19cd63c2cb5ce6231,

title = "Stent Thrombosis",

abstract = "Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.",

keywords = "acute myocardial infarction, bare-metal stent, drugeluting stent, dual antiplatelet therapy, percutaneous coronary intervention, stent thrombosis",

author = "Holmes, {David R.} and Kereiakes, {Dean J.} and Scot Garg and Serruys, {Patrick W.} and Dehmer, {Gregory J.} and Ellis, {Stephen G.} and Williams, {David O.} and Takeshi Kimura and Moliterno, {David J.}",

note = "Funding Information: Dr. Kereiakes has received a grant and/or research support from Abbott Vascular , Cordis/Johnson & Johnson , Boston Scientific , and Medtronic ; and consulting fees from Abbott Vascular, Boston Scientific, Cordis/Johnson & Johnson, Devax, and REVA Medical Inc. Dr. Ellis is a consultant for Abbott Vascular, Boston Scientific, and Cordis. Dr. Williams is a consultant for Cordis. Dr. Kimura is an advisory board member for Codis Cardiology and Abbott Vascular. Dr. Moliterno is a consultant for Boston Scientific, Merck/Schering-Plough, Daiichi-Sankyo, and Sanofi-Aventis. All other authors report that they have no relationships to disclose. ",

year = "2010",

month = oct,

day = "19",

doi = "10.1016/j.jacc.2010.07.016",

language = "English",

volume = "56",

pages = "1357--1365",

number = "17",

}

TY - JOUR

T1 - Stent Thrombosis

AU - Holmes, David R.

AU - Kereiakes, Dean J.

AU - Garg, Scot

AU - Serruys, Patrick W.

AU - Dehmer, Gregory J.

AU - Ellis, Stephen G.

AU - Williams, David O.

AU - Kimura, Takeshi

AU - Moliterno, David J.

N1 - Funding Information: Dr. Kereiakes has received a grant and/or research support from Abbott Vascular , Cordis/Johnson & Johnson , Boston Scientific , and Medtronic ; and consulting fees from Abbott Vascular, Boston Scientific, Cordis/Johnson & Johnson, Devax, and REVA Medical Inc. Dr. Ellis is a consultant for Abbott Vascular, Boston Scientific, and Cordis. Dr. Williams is a consultant for Cordis. Dr. Kimura is an advisory board member for Codis Cardiology and Abbott Vascular. Dr. Moliterno is a consultant for Boston Scientific, Merck/Schering-Plough, Daiichi-Sankyo, and Sanofi-Aventis. All other authors report that they have no relationships to disclose.

PY - 2010/10/19

Y1 - 2010/10/19

N2 - Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.

AB - Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its morbidity and mortality. Because little advance has been made in outcomes following ST, ongoing research is focused on further understanding predictive factors as well as ST frequency and timing in various patient subsets, depending upon whether a drug-eluting stent or bare-metal stent has been implanted. Although the preventive role of antiplatelet therapies remains unchallenged, new data on genomics and variability in response to antiplatelet therapy, as well as the effects of novel therapeutic agents and duration of therapy, have become available. The goal remains identification of patients at particularly increased risk of ST so that optimal prevention strategies can be developed and employed.

KW - acute myocardial infarction

KW - bare-metal stent

KW - drugeluting stent

KW - dual antiplatelet therapy

KW - percutaneous coronary intervention

KW - stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=77957930169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957930169&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2010.07.016

DO - 10.1016/j.jacc.2010.07.016

M3 - Review article

C2 - 20946992

AN - SCOPUS:77957930169

SN - 0735-1097

VL - 56

SP - 1357

EP - 1365

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 17

ER -

Stent Thrombosis

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this